Waverley Pharma Inc.
WAVE.V
TSX
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -374.10% | -203.65% | 13.64% | 92.02% | 87.19% |
| Total Depreciation and Amortization | -1.34% | 0.00% | 520.83% | -- | -- |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 488.89% | -50.00% | 149.77% | -158.45% | -84.48% |
| Change in Net Operating Assets | 134.28% | 12.53% | -98.15% | -166.31% | -218.19% |
| Cash from Operations | 58.44% | -157.48% | -393.88% | 72.99% | -35.34% |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -100.00% | 100.00% | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -- | -100.00% | 100.00% | -- | -- |
| Total Debt Issued | 196.92% | 142.71% | -90.99% | -68.14% | -71.29% |
| Total Debt Repaid | 2.33% | 21.21% | -- | -- | -- |
| Issuance of Common Stock | -- | -- | -- | -- | -- |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 281.33% | 162.81% | -92.17% | -71.69% | -80.24% |
| Foreign Exchange rate Adjustments | -- | -134.09% | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 126.44% | -579.17% | -142.81% | 225.00% | -8,137.50% |